Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Oakmark Global Fund 2026 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Oakmark Global Fund)

Primary Source Intelligence • Q2 2026 Letter Analysis

Oakmark Global Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Oakmark Global Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+7.89%

YTD+1.84%

Annualized+9.32%

Positioning StanceNEUTRAL

Market CapLarge Cap

GeographyEurope, Global, US

Digest Analysis

Quick Take

"Underperforming on AI enthusiasm but maintaining long-term outperformance. Samsung rallied on AI-driven memory demand while BMW fell on China weakness."

Executive Summary

The Oakmark Global Fund returned 7.89% in Q2 2026, underperforming the MSCI World Index but maintaining outperformance since inception. The portfolio remains concentrated in the U.S. (52.1%), Europe ex U.K. (35.5%), and the U.K. (5.6%), with emerging markets at 4.9%. Samsung Electronics was the top contributor, rallying on record profits driven by AI-related semiconductor demand, particularly in high-bandwidth memory where supply trails demand. BMW was the top detractor after cutting guidance on weaker Chinese demand and Middle East impacts, though the managers view the Neue Klasse launch positively long-term. The Fund initiated five new positions in quality businesses trading at discounts: AstraZeneca (pharmaceuticals facing regulatory concerns), Cooper Companies (medical devices), LVMH (luxury goods pressured by China weakness), Owens Corning (building products), and Symrise (specialty chemicals). The managers continue evaluating companies based on competitive advantages and long-term cash flows rather than speculating on AI trends, finding selective opportunities where near-term headwinds have created attractive valuations for patient capital.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The Fund holds a concentrated portfolio with 11 named positions discussed in detail, including specific position sizing language (Samsung at 3.7%, BNP Paribas at 3.2%, Symrise at 2.5%). The managers provide detailed, multi-paragraph theses for five new purchases with specific competitive advantage analysis and valuation frameworks. Language is declarative with phrases like 'we believe,' 'we continue to view,' and 'in our view' supporting clear directional views. However, the portfolio appears to hold more than 15 total positions based on the percentage allocations shown, and some hedging language exists ('we expect,' 'should drive'). The detailed analysis of individual holdings and willingness to initiate new positions at current valuations supports a moderate-to-high conviction score.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The letter acknowledges AI enthusiasm as a defining market theme and notes selective opportunities across sectors, but also highlights multiple headwinds including economic uncertainty, cyclical pressures, weaker Chinese demand, and regulatory concerns. The tone is constructive but measured, with the managers finding opportunities in dislocated areas rather than expressing broad market optimism. The balanced view of opportunities amid challenges supports a mildly positive score.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

The Fund initiated five new positions during the quarter while completing four sales, indicating selective deployment. The managers are putting capital to work in areas they view as attractively valued (pharmaceuticals, medical devices, luxury, building products, specialty chemicals) but are doing so selectively based on valuation dislocations rather than broad risk-on positioning. The 4.9% emerging markets allocation and focus on quality businesses with competitive advantages suggests a measured risk appetite rather than aggressive deployment.

Capital Deployment

25%

De-riskingDeploying

De-risking (25%)

The Fund initiated five new positions (AstraZeneca, Cooper Companies, LVMH, Owens Corning, Symrise) while completing four sales (Akzo Nobel, Charter Communications, Roche Holding, Waters), representing net positive activity. However, without specific cash level data, this appears to be primarily rotation rather than aggressive net deployment. The language emphasizes 'selective opportunities' and 'attractive entry points' rather than aggressive deployment. The net addition of one position and the selective nature of purchases supports a modest positive deployment score.

Forward Guidance

35%

CautiousExpansionary

Cautious (35%)

The managers state they will continue to evaluate companies based on competitive advantages, long-term cash flows, and valuation rather than speculating on trends. They are finding selective opportunities where near-term headwinds have created attractive entry points. The language suggests continued selective deployment in quality businesses at discounts, but with patience and discipline rather than urgency. The focus on 'selective opportunities' and 'attractive entry points' indicates a mild deployment bias.

Language Signal

30%

BearishBullish

Bearish (30%)

The letter uses opportunity-oriented language including 'attractive entry point' (used multiple times), 'well positioned,' 'attractive growth profile,' 'quality business,' and 'discounted valuation.' However, this is balanced by risk language including 'economic uncertainty,' 'cyclical forces,' 'weighed on sentiment,' 'come under pressure,' 'concerns,' and 'headwinds.' The net balance tilts slightly positive as the managers frame challenges as creating opportunities, but the language is measured rather than enthusiastically bullish.

Perceived Risk

52%

Low RiskElevated

Moderate Risk (52%)

The letter identifies multiple specific risks with meaningful discussion: economic uncertainty and cyclical forces in building products, luxury goods market pressure from U.S. demand moderating and Chinese macro backdrop difficulties, U.S. pharmaceutical regulations weighing on the sector, and weaker Chinese demand plus Middle East conflict impacting autos. These are named, sector-specific risks discussed in context of individual holdings. However, the risks are framed as creating opportunities rather than systemic threats, and there are no warnings of tail risks or crisis scenarios. The moderate level of risk acknowledgment with opportunity framing supports a mid-range score.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

The managers initiated five new positions during the quarter across diverse sectors (pharmaceuticals, medical devices, luxury, building products, specialty chemicals), indicating they are finding multiple attractive opportunities. The language emphasizes 'selective opportunities,' 'attractive entry points,' and 'rare opportunity' suggesting opportunities exist but require selectivity. The ability to deploy capital across multiple sectors at valuations the managers view as compelling, combined with the selective framing, supports a moderately high opportunity density score.

Time Horizon

72%

Short-TermLong-Term

Decade+ (72%)

The letter emphasizes 'long-term cash-flow potential,' 'well positioned long term,' 'over the long term,' and 'for years to come' throughout. The managers discuss multi-year thesis elements including AstraZeneca's pipeline driving 'strong growth for years to come,' Samsung positioned to benefit 'over the long term,' and LVMH's ability to 'deliver attractive organic growth and returns through cycles.' The focus on competitive advantages, intrinsic value, and willingness to invest through near-term headwinds indicates a multi-year horizon. However, some catalyst dependency exists (Neue Klasse launch, industry recovery expectations) preventing a score above 0.75. The clear multi-year perspective with limited near-term urgency supports a moderately high time horizon score.